<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961348</url>
  </required_header>
  <id_info>
    <org_study_id>U-2015-341</org_study_id>
    <secondary_id>2015-00881</secondary_id>
    <nct_id>NCT02961348</nct_id>
  </id_info>
  <brief_title>TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation</brief_title>
  <official_title>Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation: a Prospective Multicenter Registry-based Non-inferiority Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Stroke Register (Riksstroke)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare early with late start of treatment with Non-vitamin K oral
      anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation;
      it is a registry-based randomized clinical trial (R-RCT) using The Swedish Stroke Register
      (Riksstroke). Half of the patients will start NOAC early (within 4 days after stroke onset)
      while the other half will start late (5-10 days after stroke onset).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral anticoagulation therapy is well established and highly recommended for the prevention of
      recurrent ischemic stroke in patients with atrial fibrillation, but the optimal time point to
      start after an acute ischemic stroke is not known.

      The intervention in this study will be timing of treatment onset. The choice of NOAC (i.e.
      apixaban, dabigatran, edoxaban or rivaroxaban) after the acute ischemic stroke is at the
      discretion of the treating physician.

      This study will use the Swedish Stroke Register for enrolment, randomization and follow-up,
      with additional data linkage from other mandatory national registers. Primary outcome will be
      assessed at 90 days and secondary outcomes (including all-cause mortality and health economic
      analyses) and will be assessed at 90 days and up to one year after the index ischemic stroke.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of recurrent ischemic stroke, symptomatic intracerebral hemorrhage, or all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent acute ischemic stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as a new focal neurological deficit of sudden onset lasting at least 24 h (or &lt;24 h if following therapeutic intervention, i.e. thrombolysis or thrombectomy, or if the deficit results in death &lt; 24 h), occurring &gt;24 hours after the index ischemic stroke, irrespective of vascular territory and that is not attributable to edema, brain shift, hemorrhagic transformation, intercurrent illness, hypoxia, or drug toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral hemorrhage (S-ICH)</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as a new focal neurological deficit of sudden onset lasting at least 24 h with documented intracerebral hemorrhage (ICH) on imaging (computed tomography (CT) or magnetic resonance imaging (MRI)). Any intraparenchymal hematoma (≥10mm) will be considered, including hemorrhagic transformation of the index ischemic stroke. However microhemorrhages (&lt;10mm) are not considered to be an ICH. ICH will be classified as symptomatic if it is associated with ≥4 points in total NIHSS or ≥2 points in one NIHSS category</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Defined by grade on the modified Rankin Scale (mRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhages</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as bleedings that are fatal or life-threatening (according to the definition by the International Society on Thrombosis and Haemostasis) or lead to hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Early start of NOAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1 to day 4 after ischemic stroke onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late start of NOAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 5 to day 10 after ischemic stroke onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early start of NOAC</intervention_name>
    <description>Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation</description>
    <arm_group_label>Early start of NOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Late start of NOAC</intervention_name>
    <description>Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation</description>
    <arm_group_label>Late start of NOAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (≥ 18 years) with acute ischemic stroke and atrial fibrillation

          -  Eligible and willing to start (or re-start) NOAC

          -  Registered in The Swedish Stroke Register

          -  Signed informed consent

        Exclusion Criteria:

          -  Contraindication to NOAC (e.g. ongoing bleeding, mechanical heart valve prosthesis)

          -  Ongoing therapy with NOAC (without ≥2 days interruption at index stroke)

          -  International normalized ratio (INR)&gt;1.7

          -  No second brain imaging (CT/MRI) after thrombolysis/thrombectomy

          -  Previous randomization in the TIMING study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Oldgren, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Medical Sciences, Uppsala University, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Signild Åsberg, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Medical Sciences, Uppsala University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Heller, PhD</last_name>
    <phone>+46186119551</phone>
    <email>susanne.heller@ucr.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Signild Åsberg, MD. PhD</last_name>
    <email>signild.asberg@medsci.uu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alingås Hospital</name>
      <address>
        <city>Alingsås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brita Eklund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Enköping Hospital</name>
      <address>
        <city>Enköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mikael Wiklund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mälarsjukhuset Hospital</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bo Danielsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Falu Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joakim Hambraeus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ritva Jokela</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallands Hospital</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Thomasson Sommer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hässleholm Hospital</name>
      <address>
        <city>Hässleholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grodon Krzysztof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kristianstad Hospital</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Svensson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kungälv Hospital</name>
      <address>
        <city>Kungälv</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Merja Henning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Motala Hospital</name>
      <address>
        <city>Motala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf Rosengren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nyköping Hospital</name>
      <address>
        <city>Nyköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Görel Wachtmeister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oskarshamn Hospital</name>
      <address>
        <city>Oskarshamn</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bongomin Churchill Otto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skaraborg Hospital</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Björn Cederin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Lundström</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrika Löfmark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyd University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth Rooth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundsvall County Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fredrick Björck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Per Wester</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Signild Åsberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallands Hospital</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Berntsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral anticoagulants (NOAC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

